TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer

NACompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

May 22, 2014

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Liver, Cancer of, Non-Resectable
Interventions
DEVICE

TheraSphere

TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.

Trial Locations (1)

75203

The Liver Institute at Methodist Dallas Medical Center, Dallas

All Listed Sponsors
lead

Methodist Health System

OTHER

NCT04090645 - TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer | Biotech Hunter | Biotech Hunter